source
- Biokin's EGFR-HER3 bispecific ADC succeeds in late-stage Chinese lung cancer trialChinese biotech Biokin announced that its EGFRxHER3 bispecific antibody-drug conjugate met its primary endpoint in a late-stage trial in a genetically defined subset of non-small cell lung cancer (…
- AstraZeneca reports positive late-stage results for Tagrisso-Orpathys combo and Enhertu in lung cancerAstraZeneca said on Monday that two separate late-stage studies in lung cancer have produced positive outcomes. One study evaluated a combination of the tyrosine-kinase inhibitor Tagrisso with the…